Keros Therapeutics (NASDAQ:KROS) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13), Briefing.com reports. The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.33) earnings per share.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $67.99 on Friday. The firm’s 50-day moving average is $57.30 and its two-hundred day moving average is $51.99. The company has a market capitalization of $2.55 billion, a PE ratio of -13.09 and a beta of 1.23. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on KROS shares. Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating on the stock. Guggenheim initiated coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday. Finally, Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $88.89.

Insider Activity

In other news, Director Carl L. Gordon sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.90% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.